Antibody-mediated rejection: a single center experience at Tokyo Women's Medical University.
AMR is one of the most important risk factors for long-term graft loss and obviously prevention of AMR would be a most effective treatment to obtain excellent long-term graft survival. We can now detect low levels of anti-HLA antibodies using solid-phase and bead-based assays and our data show that these low levels of anti-HLA antibodies, especially DSA, could be a very important marker for AMR after renal transplantation. Once we can detect these antibodies, we have effective means to desensitize the patients prior to renal transplantation.
Tanabe
Kazunari
K
Department of Urology, Graduate School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Ishida
Hideki
H
Omoto
Kazuya
K
Shimizu
Tomokazu
T
Shirakawa
Hiroki
H
D000017:ABO Blood-Group System; D000328:Adult; D000368:Aged; D001787:Blood Group Incompatibility; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012086:Reoperation / Q000706:statistics & numerical data; D012189:Retrospective Studies; D014041:Tokyo; D016896:Treatment Outcome
D000017:ABO Blood-Group System; D007166:Immunosuppressive Agents; D007518:Isoantibodies